MRRS adds "Frontier Pharma: Chronic, Acute and Neuropathic Pain – GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain as a disease, rather than just as a symptom of a primary cause. In the US, pain affects more people than cancer, diabetes and heart disease combined, with an estimated 100 million people having experienced at least one chronic pain episode in the last 12 months, at an annual cost of around $600 billion in medical treatment and lost productivity.

The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established product categories, active pharmaceutical ingredients and concomitant mechanisms of action.

Moderate-to-severe pain has been and continues to be dominated by opioids, which are increasingly being reformulated to offer abuse-resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (NSAID). However, significant unmet needs remain, as chronic pain subtypes – and particularly neuropathic pain – do not respond well to existing therapies, which do not align to the underlying molecular pathophysiological profile of pain.

However, strong unmet needs remain in core therapy types such as NSAIDs, which are associated with often severe gastrointestinal adverse events (AE), and opioids, which have a range of AEs associated with them – in addition to the potential for abuse, which has not been fully alleviated by the development of abuse-deterrent formulations.

Table of Contents
1 Table of Contents 2
1.1 List of Tables 2
1.2 List of Figures 3
2 Executive Summary 4
2.1 Substantial Unmet Needs Remain in Core Therapy Types 4
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline 4
2.3 Rich Pipeline Landscape with Numerous Investment Opportunities 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Development Remains Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.1.1 Chronic and Neuropathic Pain 10
4.1.2 Disease Pathophysiology 11
4.1.3 Diagnosis 14
4.1.4 Treatment Options 15
4.2 Overview of Marketed Products for Pain 15
4.2.1 Analgesic Product Categories 16
4.2.2 Molecular Type Analysis 17
4.2.3 Current Unmet Needs 18
5 Assessment of Pipeline Product Innovation in Chronic, Acute and Neuropathic Pain 20
5.1 Pain Pipeline by Molecule Type, Stage of Development and Molecular Target 20
5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family 23
5.3 First-in-Class Pipeline Programs 23......

List of Tables and Figures 
Table 1: Pain Market, Global, Categories of Pain, 2016 10
Table 2: Pain Market, Global, Data for Nerve Growth Factor as a Molecular Target, 2016 36
Table 3: Pain Market, Global, Data for High Affinity Nerve Growth Factor Receptor as a Molecular Target, 2016 36
Table 4: Pain Market, Global, Data for Tumor Necrosis Factor Receptor Superfamily Member 16 as a Molecular Target, 2016 38
Table 5: Pain Market, Global, Data for Bradykinin B1 Receptor as a Molecular Target, 2016 40
Table 6: Pain Market, Global, Data for Opioid Receptor-Like-1 Receptor as a Molecular Target, 2016 42
Table 7: Pain Market, Global, Data for Purinoceptor 7 as a Molecular Target, 2016 44
Table 8: Pain Market, Global, Data for Metabotropic Glutamate Receptor 6 as a Molecular Target, 2016 45
Table 9: Pain Market, Global, Data for Metabotropic Glutamate Receptor 7 as a Molecular Target, 2016 45
Table 10: Pain Market, Global, Data for Calcitonin Gene-Related Peptide Type-1 Receptor as a Molecular Target, 2016 46
Figure 1: Pharmaceutical Market, Global, Innovation Trends in Product Approvals, 1987-2012 5
Figure 2: Pharmaceutical Market, Global, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013 7
Figure 3: Pain Market, Global, Treatment Algorithm 15
Figure 4: Pain Market, Global, WHO Analgesic Ladder 16
Figure 5: Pain Market, Global, Marketed Products by Molecule Type and Molecular Target, 2016 18
Figure 6: Pharmaceutical Market, Global, Developmental Pipeline Overview, 2016 20.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/frontier-pharma-chronic-acute-and-neuropathic-pain-gpcr-and-nerve-growth-factor-based-therapies-offer-strong-potential-in-difficult-to-treat-subtypes

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/